Open-label study for the patients with otorhinolaryngological infection
Phase 3
Completed
- Conditions
- Secondary infection of chronic respiratory disease and acute bronchitis
- Registration Number
- JPRN-jRCT2080222863
- Lead Sponsor
- Kyorin Pharmaceutical Co.,LTD
- Brief Summary
Once daily administration of KRP-AM1977X was highly effective for otolaryngological infections.In the safety assessment, no major problem was observed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Otorhinolaryngological infection with clear infection symptoms
Exclusion Criteria
Patient with serious functional disorder that would unsuitable for the study
Patient showing the tendency to improve symptoms by other agents
etc
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy<br>Clinical efficacy at the end of treatment
- Secondary Outcome Measures
Name Time Method efficacy<br>Clinical efficacy rate at the test of cure, etc